Top of page Skip navigation
  • CHECK-OUT OUR SUPPORTER PACKAGES

    Only a few options remain for this leading conference

Speakers

Steve Bagshaw

Chief Executive Officer, FUJIFILM Diosynth Biotechnologies

Steve Bagshaw

Chief Executive Officer, FUJIFILM Diosynth Biotechnologies

Steve has global responsibility for all FUJIFILM Diosynth business activities reporting directly to FUJIFILM Corporation in Tokyo.  He is based in Billingham on Teesside. 

 

Steve is also Chair of the UK Industrial Biotechnology Leadership Forum.  He is currently Co-Chairing the UK Bioeconomy Strategy Programme Board and is a Director of NEPIC (North East Process Industry Cluster).

 

FUJIFILM Diosynth are one of the world’s leading Biopharmaceutical Contract Development and Manufacturing Organisations,

Steve Bates OBE

Chief Executive Officer, BIA

Steve Bates OBE

Chief Executive Officer, BIA

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

 

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

 

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations.  An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Dr Crawford Brown

Senior Vice President R&D, Allergan Biologics

Dr Crawford Brown

Senior Vice President R&D, Allergan Biologics

Crawford is global head of Biologics R&D managing the design, development and delivery of biological medicines to patients from Allergan’s labs in Irvine California and Liverpool, UK.  He manages Allergan’s capabilities in Bacterial (anaerobic/aerobic), Mammalian and Viral production. Allergan operate an open science model partnering and acquiring biologics from pre-clinical to late stage, Crawford sits on five Alliance Steering Committees related to Biosimilars, GI MAbs, CRISPR Viral Gene Therapy, Microbiome and Retinal Ophthalmology Biologics.

 

Crawford has spent over 30 years developing biological medicines with particular expertise in process validation and registration with EMA, FDA and PMDA. Crawford co-founded Eden Biodesign Ltd as CEO in 2000 through to its acquisition by Allergan in 2010, by which point the company had grown to over 100 staff in UK and USA.

 

Prior to Allergan, Crawford held senior technical management positions in British Biotech, Celltech-Medeva and Wellcome.

 

In 2012 Crawford was presented with The Peter Dunnill Award and has served on the UK Medicines Manufacturing Industry Partnership, BBSRC Bioprocessing Research Industry Club and South Liverpool Economic Development Partnership.  Crawford holds a BSc in Applied Microbiology and a PhD in Chemical and Process Engineering from Strathclyde University.  

Dr Steve Chatfield

Chairman, Prokarium

Dr Steve Chatfield

Chairman, Prokarium

Steve has spent more than 35 years working in the field of research and development within the Biopharma industry and now works as an independent consultant. His career has focussed on leading the development of new healthcare interventions with a particular emphasis on vaccines and immunotherapy products to combat infectious disease, including experience in the biodefense sector.  He is currently holds Non-Executive Board positions in Prokarium, Vaccitech and the Cell and Gene Therapy Catapult.

 

His previous roles include executive positions at Medeva plc, Microscience Ltd, and Emergent Biosolutions.  Steve also served as an Executive Director of the Health Protection Agency where he was responsible for emergency preparedness and response.  He is passionate about translational research – driving new technologies and products towards commercialisation and has a thorough understanding of the product development process, from research to product launch.  Steve holds a PhD in microbiology and has published more than 100 papers in the field of biotechnology.

Dr Nigel Darby

Executive Advisor, GE Healthcare Life Sciences

Dr Nigel Darby

Executive Advisor, GE Healthcare Life Sciences

Nigel joined GE Healthcare Life Sciences in 2003 and was Vice President of the BioProcess business until 2016. The business develops manufacturing technology, which is used in the production of most of the worlds biopharmaceuticals. He is currently an advisor to the CEO and a board member of Vineti Inc. and Asymptote Ltd.

 

From 1997 to 2003 Nigel held positions with AstraZeneca, finally as Vice President Chemistry Technology.  In this role, he led the development of new approaches to drug discovery and a global network of technology groups.

 

Prior to entering industry Nigel had spent 16 years in academic research at NIMR, London, LMB, Cambridge, and EMBL, Heidelberg, Germany.

 

He received his BA in Natural Sciences from the University of Cambridge in 1981 and his PhD in Biochemistry from the University of Kent in 1985.

Professor Alan Dickson

Professor of Biotechnology, University of Manchester

Professor Alan Dickson

Professor of Biotechnology, University of Manchester

Alan is Professor of Biotechnology at the University of Manchester with BSc and PhD from The University of Edinburgh.  He is a molecular cellular biologist and works with industrial partners to enhance expression and manufacture of recombinant proteins in bioprocessing.

 

Current grant funding includes Research Council and industrially funded projects.  He is a member of the Steering Group of the BBSRC Bioprocessing Research Industry Club (BRIC) and the Executive Committee of the European Society for Animal Cell Technology (ESACT).  He leads the multi-disciplinary Centre of Excellence in Biopharmaceuticals (COEBP) based in the Manchester Institute of Biotechnology.  The COEBP links researchers from biological, chemical, chemical engineering, medical and physical sciences backgrounds, applying novel approaches to challenges of manufacture of biologics, promoting industrial-academic linkages and providing access to research technologies including high-throughput and high-content cell culture robotics.

 

Alan is Co-Director of BioProNET, a BBSRC NIBB co-sponsored by EPSRC, which promotes industrial-academic interactions.

Andy Evans

Head of Macclesfield Site, AstraZeneca UK

Andy Evans

Head of Macclesfield Site, AstraZeneca UK

Andy is the Site Manager at Macclesfield which is AstraZeneca’s second biggest manufacturing site and supplies Tablets, Sterile Devices and Parenteral and Tablet packs to around 130 markets globally.

 

Andy is a Fellow of the Institute of Chemical Engineers and has worked for ICI, Zeneca and AstraZeneca since 1987.

 

Andy has worked across Supply Chain Management, Major Capital and IS projects, Engineering and Manufacturing Management during his career and is currently chairman of the Medicines Manufacturing Industry Partnership

Dr Jim Faulkner

Head of Manufacturing, Autolus

Dr Jim Faulkner

Head of Manufacturing, Autolus

Jim is responsible for process development, manufacturing and supply chain for Autolus, a recently-formed spin-out from University College London (UCL) that is specialising in T-cell immunotherapy using Chimeric Antigen Receptor technology. Autolus is pursuing a number of targets with the aim of improving treatments for both haematological and solid cancers.

 

Previously, Jim was head of manufacturing and supply for the rare diseases unit at GlaxoSmithKline, where he played an important role in developing their ex vivo gene therapy portfolio for serious rare childhood diseases.

 

Jim obtained his PhD in molecular biology in association with the University of Kent.  He has a track record of publications and patents in the biopharm field.

Dr Markus Gershater

Chief Scientific Officer, Synthace

Dr Markus Gershater

Chief Scientific Officer, Synthace

Markus has a background in biochemistry with a PhD from Durham University.  From there he moved into industry, where he developed and optimised bioprocesses for the Pharmaceutical and Agrochemical applications using high dimensional optimisation methods (Design of Experiments).  

 

Marcus then moved back into Academia, taking a postdoctoral position at University College London, focussed on using synthetic biology for pathway engineering.  Markus cofounded Synthace in 2011.

Dr Ryan Guest

Director of Cell Production and Co-founder, Cellular Therapeutic

Dr Ryan Guest

Director of Cell Production and Co-founder, Cellular Therapeutic

Ryan is a Director Cell Production at Cellular Therapeutics Ltd (CTL). He has more than a decade of experience in the design, development and implementation of cGMP cell therapy manufacturing and two decades of experience of working in the field of adoptive T cell therapy (TIL, CAR, TCR).

 

Ryan leads, CTLs partnerships with academic and industry in designing cell therapy manufacturing processes, QC and regulatory packages to deliver high quality cell based AT(I)MPs to enable healthcare organisations to treat patients.  This has been based on CTLs early adoption in the design and implementation of clean room free technologies, back in 2010, enabling increased parallel cellular therapy product manufacturing.

 

Ryan also has a wealth of experience in designing and setting up sophisticated, state-of-the-art, GMP compliant facilities, having lead the team to install, and subsequently expand and update, CTL's MHRA and HTA authorised GMP certified AT(I)MP manufacturingfacility. 

Dr Oliver Hardick

Chief Executive Officer, Puridify

Dr Oliver Hardick

Chief Executive Officer, Puridify

Oliver is the founder of Puridify, a venture backed bioprocessing technologies company based near London, UK.

 

Oliver completed his Engineering doctorate at UCL in the department of Biochemical Engineering headed up by Prof Nigel Titchener-Hooker where the initial purification technology, FibroSelect, was developed under the supervision of Prof Dan Bracewell, and Oliver continues to represent UCL as an honorary lecturer. His expertise lie in the field of novel purification approaches in bioprocessing and is experienced at delivering successful large multidisciplinary R&D projects.

 

Puridify is developing and commercialising novel bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new biomolecule products.

 

Since incorporation in 2013 Puridify has raised $12 million from both private and public sources and currently has ~20 people working to develop and commercialise the FibroSelect platform technology.

Professor Mark Haworth

Co-founder, SpyBiotech

Professor Mark Haworth

Co-founder, SpyBiotech

Mark founded SpyBiotech in March 2017 with colleagues Jing Jin, Sumi Biswas and Simon Draper of Oxford University.  Mark has been a group leader in Oxford University Department of Biochemistry since 2007.  He did postdoctoral studies at MIT with Alice Ting, where he developed monovalent streptavidin and single molecule probes for tracking neurotransmitter receptors.

Mark’s doctoral work was with Tim Elliott at Southampton University on MHC class I-peptide quality control.  His current academic work is on innovating ultra-stable protein interactions through engineering of bacterial peptide superglues.  These tools are being applied to enzyme stabilization and multimerization of antibodies and antibody-like molecules for cancer detection and killing.

John Hodgson

Executive Editor, Informa

John Hodgson

Executive Editor, Informa

John is Executive Editor at Informa, working for Scrip Intelligence and In Vivo.  He has been a commentator on the biotechnology and healthcare industries for over 35 years, first as a science and business editor (Trends in Biotechnology, Nature Biotechnology) and then as a consultant (clients included the European Commission and UK government, venture-backed start-ups, multinationals in pharmaceuticals and agriculture, and industry associations). 

John currently explores disconnections between science and industry, between announcements and delivery, and between words and numbers. 

Bo Kara

Head Process Development, GlaxoSmithKline

Bo Kara

Head Process Development, GlaxoSmithKline

Bo leads the development of manufacturing processes for GSK’s cell gene therapy viral vector and ex-vivo autologous cell drug products.  He has nearly 30 years’ experience in designing R&D programmes to develop scalable, operable and validatable manufacturing processes for biologics products. After leaving University, Bo joined the brewing industry for a short period prior to joining the newly formed Biotechnology Group at ICI Pharmaceuticals/Zeneca/AstraZeneca.

 

Just after the merger of Zeneca-Astra, Bo joined Avecia (which later became MSD, then Fujifilm) to lead Science and Technology platform development.

 

He has published widely and is primary inventor on a range of biologics process/stem cell patents

Dr Peter Levison

Senior Marketing Director - Downstream Processing, Pall Life Sciences

Dr Peter Levison

Senior Marketing Director - Downstream Processing, Pall Life Sciences

Peter is responsible to the biopharmaceutical business for the global product management of the continuous processing portfolio of products and process chromatography columns and systems. This embraces continuous processing technologies including those based upon acoustic wave separation, multi-column chromatography and Single Pass TFF.  Peter joined Pall in July 2003 but has over 20 years experience in the biopharmaceutical industry, holding positions of increasing responsibility in research and development, technical management, and product management.

 

Peter holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Dept. of Biochemistry, University of Manchester.  He has an MBA awarded through the Open University Business School, Milton Keynes, UK.  He is a member of various professional bodies and has the status of C.Chem, FRSC (Chartered Chemist and Fellow of the Royal Society of Chemistry in the UK) and C.Biol, FRSB (Chartered Biologist and Fellow of the Royal Society of Biology in the UK)

Dr John Liddell

Senior Scientific Advisor, Centre for Process Innovation

Dr John Liddell

Senior Scientific Advisor, Centre for Process Innovation

John is currently Senior Scientific Advisor, National Biologics Manufacturing Centre, a UK-based technology innovation centre part of the Centre for Process Innovation and the UK Catapult network.

 

John has previously worked as a consultant to the biopharmaceutical industry. Prior to that he held senior bioprocess development roles at FUJIFILM Diosynth Biotechnologies, Merck &Co, Avecia Biologics, Zeneca and ICI.  John has almost 30years of broadly based experience in bioprocessing and protein chemistry and has experience of a wide range of biopharmaceutical products from all popular expression systems.

 

He has been directly involved in all phases of bioprocess development from preclinical and early phase process definition through to late phase process and product characterisation as well as process validation. He has been responsible for development and implementation of innovative process technologies. 

Ian McCubbin

Lead, Advanced Therapies Manufacturing Task Force

Ian McCubbin

Lead, Advanced Therapies Manufacturing Task Force

Ian moved into his latest role as SVP North America, Japan and Global Pharma Supply within the Global Manufacturing and Supply (GMS) division of GlaxoSmithKline plc (GSK) in January 2013.  Ian joined GSK in 2006, his second spell with the company, and has responsibility for GSK’s in-market supply chain and distribution throughout North America and Japan.  This includes overseeing 17 factories and 7,000 employees globally.

 

Ian is a pharmacist and a member of the Royal Pharmaceutical Society GB with 30 years’ experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership in both the generic sector and the branded sector of the industry.

 

He is a founding Board Director of ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer in 2009 to deliver advances in treatment and care for people living with HIV.  Shionogi joined ViiV Healthcare in 2012.  Ian also sits on GSK’s Charitable Donations Committee, which is responsible for distributing donations to aligned charities.  He is also Chair of the Medicine Manufacturing Industry Partnership (MMIP) that was jointly established by the Association of the British Pharmaceutical Industry (ABPI) and the UK BioIndustry Association (BIA) in September 2013. Ian holds a degree in Pharmacy from Heriot-Watt University, Edinburgh, is married to Barbara, also a pharmacist working in the NHS, and they have two grown up children.

Dr Damian Marshall

Head of Analytical Development, Cell and Gene Therapy Catapult

Dr Damian Marshall

Head of Analytical Development, Cell and Gene Therapy Catapult

Damian is the head of analytical development for the Cell and Gene Therapy Catapult and has over 15 years of industrial experience focussed on the development of cell therapies and the implementation of new technologies for product characterisation.  His team works closely with a wide range of cell and gene therapy developers to address some of main analytical challenges faced within the field. These include the application of inferential technologies to support closed manufacture, development of rapid surrogate assays for product release testing and the development of methods to support real time release.

 

Damian has published widely on his work and has authored a number of national and international guidance documents for the cell therapy field.

Dr Tarit Mukhopadhyay

Senior Lecturer, University College London

Professor Amit Nathwani

Professor of Haematology, UCL

Professor Amit Nathwani

Professor of Haematology, UCL

Amit, a NIHR Senior Investigator, is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital and Professor of Haematology at UCL.  He is internationally recognised for his pioneering work in gene therapy and is the recipient of the ESGCT Outstanding Achievement Award and the Human Gene Therapy Award amongst others.

 

Professor Nathwani developed a novel gene transfer approach that enabled the first successful trial of gene therapy in a bleeding disorder- haemophilia B and this has now become the platform for a variety of genetic disorders.  He has also developed a novel approach for gene therapy of haemophilia A that has resulted in normalisation of coagulation factor VIII levels and correction of bleeding diathesis in severely affected patients.  His group is working on other translational gene transfer approaches for a range of monogenetic disorders as well as malignancies.

Dr Roger New

Executive Director, Proxima Concepts

Dr Roger New

Executive Director, Proxima Concepts

Roger studied chemistry at Oxford and obtained a PhD in immunology at St Mary’s Hospital, London, worked in Liverpool at the School of Tropical Medicine and Hygiene, before setting up Proxima Concepts Ltd in 2000.  He has devised patented approaches to oral peptide delivery, vaccine carrier systems, and drug discovery.  The peptide delivery technology has given rise to oral insulin, now in Phase II clinical trials, and licensed to large pharma in an emerging market. 

 

The discovery technology has yielded structures which can act as targeting agents, and one peptide has been developed which is currently undergoing preclinical studies as a treatment for rheumatoid arthritis.  Most recently, an advanced technology designed to aid delivery of antigens to Peyer’s Patches in the intestine has shown great promise as a potential orally delivered vaccine vehicle, with particular application to protection of mucosal surfaces, and prevention of respiratory and intestinal diseases.

Jo Pisani

Partner Pharmaceuticals and Lifesciences, PwC's Strategy&

Jo Pisani

Partner Pharmaceuticals and Lifesciences, PwC's Strategy&

Jo is a Partner leading the UK Pharma and Lifesciences Consulting Practice.  She has 13 years of industry experience in the pharmaceuticals, energy, petrochemicals, and fast-moving consumer goods industries with BP and SmithKline Beecham where she held positions in the engineering, operations, IT, and commercial functions.  Before joining PwC, she spent three years with Booz&Co, a strategic management consultancy where she focused on strategic issues in the pharmaceuticals and energy sectors.

 

Jo assists the pharma and life sciences sector in developing strategy and supporting deals.  Her clients include Big Pharma, biotech, generics, OTC, contract manufacturers, contract research organisations, ministries of health, private equity and banks.  She is a key author on PwC’s Pharma2020 thought leadership series.  She is an advisory board member of MedCity.

 

Jo has an MBA from Warwick Business School and is a Chartered Engineer.

Dr Daniel Smith

Chief Scientific Officer, Cobra Biologics

Dr Kajsa Stridsberg-Friden

Senior Project Manager Downstream, GE Healthcare Life Sciences

Dr Kajsa Stridsberg-Friden

Senior Project Manager Downstream, GE Healthcare Life Sciences

Kajsa is Senior Project Manager, Downstream Processing, at GE Healthcare Life Sciences, Sweden, which is a provider of products and expertise for developers and manufacturers of biotherapeutics to enable characterization, expression and purification of biomolecules.

Kajsa graduated in Chemical engineering in 1995 and earned her doctorate in Polymer Technology in 2000 at the Royal Institute of Technology in Stockholm, Sweden.  After her PhD, Kajsa joined Amersham Pharmacia Biotech in 2000, that later became GE Healthcare.

Her work has focused on the development of surface modifications to enhance chromatography resin performance and new formats for protein separation and purification. Kajsa has since then been in various roles throughout her GE career, including Senior scientist, Line manager for the organic chemistry group, Project manager for research projects and currently as Senior project manager for new product introduction projects. 

Dr Mike Sullivan

Interim Challenge Director, Medicines Manufacturing, Innovate UK

Dr Andy Topping

Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies

Richard Turner

Director of Purification Process Sciences MedImmune

Richard Turner

Director of Purification Process Sciences MedImmune

Richard joined Cambridge Antibody Technology more than 19 years ago and has led the Purification Process development function in Cambridge since CAT was integrated into MedImmune in 2007. 

 

His group has a focus on the development of purification strategies for manufacture of MAbs and other novel molecules. Richard has an extensive network in the UK science community and is a strong advocate for developing collaborations with academic and industry partners. 

Dr Phil Vanek

General Manager, Cell Therapy Technologies, GE Healthcare

Dr Phil Vanek

General Manager, Cell Therapy Technologies, GE Healthcare

Phil is General Manager of GE Healthcare’s Cell Therapy Technologies business strategy, a business initiative funded in part by GE Healthymagination, a $6 billion strategy to revolutionise the world’s health by improving the quality, access and affordability of care.  Prior to joining GE, Phil was Head of Innovation for Lonza’s Pharmaceutical division, leading a group of research scientists, process development engineers, and commercial strategists to drive new technology initiatives focused on cell, protein, and viral therapeutic manufacturing.

 

Phil’s career has included a number of senior innovation, business and market development roles at Becton Dickinson, Invitrogen, and Life Technologies, as well as two start-up biotechnology companies in the Washington, DC area.

 

Phil received his PhD in Biochemistry and Molecular Biology from Georgetown University Medical Center and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology and the Hollings Cancer Center in Charleston, South Carolina.

 

Phil is an active board member of the Alliance for Regenerative Medicine and the Centre for Commercialisation of Regenerative Medicine (CCRM) in Toronto.  Phil has published a number of industry position pieces and serves on the Editorial Board of Cell and Gene Therapy Insights

Dr Stephen Ward

Chief Operating Officer, Cell and Gene Therapy Catapult

Dr Stephen Ward

Chief Operating Officer, Cell and Gene Therapy Catapult

Stephen was appointed Chief Operating Officer of the Cell Therapy Catapult in January 2013.  He brings over 20 years of biological medicine research, development, and manufacturing experience to the organisation.  Stephen enjoys bringing cutting edge technologies to patients, by developing commercially viable products and has developed and validated scaleable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles.

 

Prior to joining the Cell Therapy Catapult, Stephen worked for several biotech and biopharma companies.  He was Development Director at both Onyvax and Stabilitech.  At Stabilitech he led the exploitation of the company’s vaccine and biopharmaceutical stabilisation platform, and expanded it into the cell therapy arena.  At Onyvax he played a key executive role in the Immune oncology programme, and at Medeva he worked on the hepatitis immunotherapy and antigen delivery platform.  



Stephen is passionate about securing and growing the UK manufacturing and development supply chain.  He is the current Chair of the UK BioIndustry Associations (BIA) Manufacturing Advisory Committee, actively promoting and supporting UK bio-manufacturing at Government as well as grass root level.  He, also, sits on various academic Advisory Boards.  His first degree was from the University of Birmingham, specialising in Infection and Immunity, and his second degree from the Medical School of Southampton University developing group B meningococcal vaccine candidates.

Dr Sam Watts

Technical Business Development Manager, Stratophase

Dr Sam Watts

Technical Business Development Manager, Stratophase

Sam is one of the co-founders of Stratophase Ltd and is an engineer by background, with a B.Eng. in Material Science and a PhD in Optoelectronics.  He has a broad experience of developing technology for monitoring and control applications.  Sam has spent the last ten years working closely with users of upstream bioprocesses in the global biopharmaceutical industry and has developed significant expertise in the area of cell culture process and feeding strategy development.

 

Sam’s current areas of interest include adaptive process control and the paradigm shift that such techniques can offer to biomanufacturing.